Publications by authors named "Jasmine Forsyth"
Background: Immunotherapy and targeted BRAF/MEK inhibitors (i) have revolutionised the systemic management of advanced melanoma. Given the role of stereotactic radiosurgery (SRS) in the local management of brain metastases, we sought to evaluate clinical outcomes in patients with melanoma brain metastases (MBM) treated with SRS and various systemic therapies.
Methods: Patients were included if MBM were diagnosed and treated with SRS within 3 months of receiving anti-PD-1+CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK-i, BRAF-i, or conventional chemotherapy.
Article Synopsis
- - ABP 798 is a biosimilar being tested against rituximab, a treatment for non-Hodgkin lymphoma, in a clinical study called JASMINE, which involved adult patients who had not previously received anti-CD20 therapy.
- - In this study, 256 patients were randomized to receive either ABP 798 or rituximab, with assessments made on their tumor response at specific weeks; results showed that 78.0% of the ABP 798 group and 70.2% of the rituximab group had a positive overall response rate by week 28.
- - Statistical analysis indicated that ABP 798 was clinically equivalent to rituximab, as the